U.S. exports of Immunological Products, Unmixed, Not Put Up in Measured Doses (HS 300213) totaled $69.7M in August 2026.
Importers of Immunological Products, Unmixed, Not Put Up in Measured Doses paid $113K in duties in August 2026, an average duty rate of 0.54% — duty actually collected as a share of the imports that cleared customs, not the published tariff schedule.
Last updated: August 2026 dataMonoclonal antibodies and other unmixed immunological products not packaged for retail sale represent some of the highest-value pharmaceutical trade flows in the global biologics market, serving as bulk intermediates for finished biologic drug manufacturing. The US schedule provides a dedicated line for monoclonal antibodies (3002130010) alongside a broader immunological products line (3002130090), with a legacy undifferentiated line (3002130000) also present. Germany and Switzerland lead US imports under this heading, reflecting the concentration of major biopharmaceutical manufacturers and contract development organizations in those countries, with the United Kingdom and China also significant sources. Admissibility is complex; importers should consult a licensed customs broker and confirm FDA CBER or CDER authorization requirements applicable to the specific product.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
126 import shipments a month
These conditions define the boundary between bulk pharmaceutical intermediates (heading 300213) and finished or formulated biologics (heading 300215 or 300290). An immunological product that has been mixed with excipients, adjuvants, or other active substances, or that has been packaged in unit doses for retail or clinical use, would generally fall outside 300213 and require reclassification. Correct classification depends on the product's formulation state and packaging at the time of importation.
Bulk monoclonal antibodies imported as drug substances are subject to FDA oversight under either CDER (for therapeutic mAbs) or CBER (for certain diagnostic or blood-related mAbs), and the foreign manufacturing facility must hold an appropriate FDA establishment registration. Importers should also confirm whether the specific product requires an Investigational New Drug (IND) authorization or a Biologics License Application (BLA) before commercial importation is permissible.
Subheading 8 of 10 in heading 3002
Subheading 300213 · $69.7M of $4.5B
ImportsExports
Imports
$15.8MYoY · free account
Exports
$69.7MYoY · free account
12-mo low · imports
Low · free accountOver the twelve months to August 2026, the U.S. imported $203.5M of Immunological Products, Unmixed, Not Put Up in Measured Doses and exported $548.6M.
Through August 2026. Source: U.S. Census Bureau.
Trade Directory
List your company under HS 300213 — Immunological Products, Unmixed, Not Put Up in Measured Doses, so the companies trading it can find you. Be the first supplier listed.
HS10 import codes under this HS6 parent, each with its own page. Source: U.S. Harmonized Tariff Schedule.
| Code | Description | Imports for consumption | Average duty rate | Dutiable Share | Duty Collected |
|---|---|---|---|---|---|
| 3002130010 | Monoclonal Antibodies, Unmixed, Not Retail Sale | $19.3M | 0.49% | 3.25% | $95K |
| 3002130090 | Immunological Products, Unmixed, Not Retail Sale | $1.6M | 1.14% | 2.09% | $18K |
HS10 export codes under this HS6 parent, each with its own page. Source: U.S. Schedule B export classification.
| Code | Description | Export Value |
|---|---|---|
| 3002130000 | Immunological Products, Not Mixed not Retail Sale | $69.7M |
Import lines come from the U.S. Harmonized Tariff Schedule and export lines from Schedule B. The two are numbered by different agencies, so the same 10-digit code can appear in both tables describing a different product.
Exports · August 2026
destination
Germany and Japan together take 43% of it.
customs district
origin
entry
rate provision · imports
95.8% enters free of duty; duty collected equals 0.54% of imports for consumption.